Third-generation subcutaneous implantable cardioverter defibrillator and intermuscular two-incision implantation technique in patients with Arrhythmogenic cardiomyopathy: 3-year follow-up.

[1]  D. Corrado,et al.  Intermuscular two-incision technique for implantation of the subcutaneous implantable cardioverter defibrillator: a 3-year follow-up , 2023, Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing.

[2]  H. Calkins,et al.  Subcutaneous and Transvenous Defibrillators in Arrhythmogenic Right Ventricular Cardiomyopathy: A Comparison of Clinical and Quality-of-Life Outcomes. , 2022, JACC. Clinical electrophysiology.

[3]  D. Corrado,et al.  Implantable defibrillator in patients with inherited arrhythmogenic diseases: Are inapproppriate shocks preventable? , 2022, International journal of cardiology.

[4]  A. Curnis,et al.  Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter defibrillators: a propensity-matched analysis from a multicenter European registry. , 2022, Heart rhythm.

[5]  D. Corrado,et al.  Evolving Diagnostic Criteria for Arrhythmogenic Cardiomyopathy , 2021, Journal of the American Heart Association.

[6]  D. Corrado,et al.  Arrhythmogenic Cardiomyopathy—Current Treatment and Future Options , 2021, Journal of clinical medicine.

[7]  M. Biffi,et al.  Implantation technique and optimal subcutaneous defibrillator chest position: a PRAETORIAN score-based study. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  R. Kato,et al.  Myopotential Oversensing Is a Major Cause of Inappropriate Shock in Subcutaneous Implantable Defibrillator in Japan. , 2020, International heart journal.

[9]  P. Lambiase,et al.  Subcutaneous or Transvenous Defibrillator Therapy , 2020, New England Journal of Medicine.

[10]  A. Mazzanti,et al.  Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. , 2020, International journal of cardiology.

[11]  P. Lambiase,et al.  Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial , 2020, Circulation.

[12]  S. Iliceto,et al.  Ultrasound-guided serratus anterior plane block for subcutaneous implantable cardioverter defibrillator implantation using the intermuscular two-incision technique , 2020, Journal of Interventional Cardiac Electrophysiology.

[13]  D. Steven,et al.  Incidence of myopotential induction in subcutaneous implantable cardioverter-defibrillator patients: Is the oversensing issue really solved? , 2019, Heart rhythm.

[14]  D. Corrado,et al.  Subcutaneous implantable cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy: Results from an Italian multicenter registry. , 2019, International journal of cardiology.

[15]  Stefan L. Zimmerman,et al.  Retracted and Republished: A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy , 2019, European heart journal.

[16]  D. Corrado,et al.  Multicentre experience with the second‐generation subcutaneous implantable cardioverter defibrillator and the intermuscular two‐incision implantation technique , 2019, Journal of cardiovascular electrophysiology.

[17]  A. Wilde,et al.  A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. , 2019, Heart rhythm.

[18]  H. Calkins,et al.  Subcutaneous Implantable Cardioverter‐Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: A Transatlantic Experience , 2018, Journal of the American Heart Association.

[19]  A. Auricchio,et al.  Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. , 2018, Heart rhythm.

[20]  H. Clahsen,et al.  Intermuscular technique for implantation of the subcutaneous implantable cardioverter defibrillator: long-term performance and complications , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[21]  H. Calkins,et al.  Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications , 2017, Journal of the American Heart Association.

[22]  S. Iliceto,et al.  Intermuscular Two‐Incision Technique for Subcutaneous Implantable Cardioverter Defibrillator Implantation: Results from a Multicenter Registry , 2017, Pacing and clinical electrophysiology : PACE.

[23]  D. Corrado,et al.  Implantable cardioverter defibrillator therapy in young patients with cardiomyopathies and channelopathies: a single Italian centre experience , 2016, Journal of cardiovascular medicine.

[24]  A. Wilde,et al.  Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications. , 2016, Heart rhythm.

[25]  M. Link,et al.  Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2015, Circulation.

[26]  M. Link,et al.  Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. , 2014, Journal of the American College of Cardiology.

[27]  M. Link,et al.  Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia , 2010, Circulation.

[28]  M. Link,et al.  Implantable Cardioverter-Defibrillator Therapy for Prevention of Sudden Death in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2003, Circulation.